Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1986 1
1988 4
1989 7
1990 9
1991 8
1992 15
1993 17
1994 21
1995 42
1996 22
1997 37
1998 34
1999 40
2000 44
2001 53
2002 52
2003 69
2004 77
2005 80
2006 71
2007 83
2008 78
2009 90
2010 90
2011 98
2012 90
2013 103
2014 84
2015 79
2016 78
2017 76
2018 47
2019 42
2020 34
2021 37
2022 39
2023 25
2024 13

Text availability

Article attribute

Article type

Publication date

Search Results

1,710 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial).
Jones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E, Cain VA, Blasetto JW; STELLAR Study Group. Jones PH, et al. Am J Cardiol. 2003 Jul 15;92(2):152-60. doi: 10.1016/s0002-9149(03)00530-7. Am J Cardiol. 2003. PMID: 12860216 Clinical Trial.
The primary objective of this 6-week, parallel-group, open-label, randomized, multicenter trial was to compare rosuvastatin with atorvastatin, pravastatin, and simvastatin across dose ranges for reduction of low-density lipoprotein (LDL) cholesterol. ...After a dietary lea …
The primary objective of this 6-week, parallel-group, open-label, randomized, multicenter trial was to compare rosuvastatin with atorvastati …
Acute respiratory distress syndrome subphenotypes and differential response to simvastatin: secondary analysis of a randomised controlled trial.
Calfee CS, Delucchi KL, Sinha P, Matthay MA, Hackett J, Shankar-Hari M, McDowell C, Laffey JG, O'Kane CM, McAuley DF; Irish Critical Care Trials Group. Calfee CS, et al. Lancet Respir Med. 2018 Sep;6(9):691-698. doi: 10.1016/S2213-2600(18)30177-2. Epub 2018 Aug 2. Lancet Respir Med. 2018. PMID: 30078618 Free PMC article. Clinical Trial.
Although HARP-2 found no difference in 28-day survival between placebo and simvastatin, significantly different survival was identified across patients stratified by treatment and subphenotype (p<0.0001). Specifically, within the hyperinflammatory subphenotype, patients …
Although HARP-2 found no difference in 28-day survival between placebo and simvastatin, significantly different survival was identifi …
Simvastatin is Efficacious in Treating Cirrhosis: A Meta-analysis.
Zhang H, Zhang Q, Li S, Xie B. Zhang H, et al. J Clin Gastroenterol. 2022 Sep 1;56(8):e303-e312. doi: 10.1097/MCG.0000000000001732. Epub 2022 Jul 14. J Clin Gastroenterol. 2022. PMID: 35830548
Here, we performed a meta-analysis to evaluate the clinical efficacy of simvastatin in liver cirrhosis patients. METHODS: We searched PubMed, EMBASE, and Cochrane library databases for randomized controlled trials targeting simvastatin in patients with liver cirrhos …
Here, we performed a meta-analysis to evaluate the clinical efficacy of simvastatin in liver cirrhosis patients. METHODS: We searched …
Simvastatin reduces plasma membrane caveolae and caveolin-1 in uterine leiomyomas.
Afrin S, El Sabeh M, Miyashita-Ishiwata M, Charewycz N, Singh B, Borahay MA. Afrin S, et al. Life Sci. 2022 Sep 1;304:120708. doi: 10.1016/j.lfs.2022.120708. Epub 2022 Jun 12. Life Sci. 2022. PMID: 35705139 Clinical Trial.
AIMS: Uterine leiomyomas, or fibroids, are estrogen dependent benign tumor in women, however, they have limited treatment options. Simvastatin, a drug commonly used to treat high cholesterol. Recently we demonstrated that simvastatin alters estrogen signaling by red …
AIMS: Uterine leiomyomas, or fibroids, are estrogen dependent benign tumor in women, however, they have limited treatment options. Simvas
Evaluation of Simvastatin as a Disease-Modifying Treatment for Patients With Parkinson Disease: A Randomized Clinical Trial.
Stevens KN, Creanor S, Jeffery A, Whone A, Zajicek J, Foggo A, Jones B, Chapman R, Cocking L, Wilks J, Webb D, Carroll C; PD STAT Study Group. Stevens KN, et al. JAMA Neurol. 2022 Dec 1;79(12):1232-1241. doi: 10.1001/jamaneurol.2022.3718. JAMA Neurol. 2022. PMID: 36315128 Free PMC article. Clinical Trial.
In the simvastatin arm, participants entered a 1-month phase of simvastatin, 40 mg daily, followed by 23 months of simvastatin, 80 mg daily, before a 2-month washout period. ...A total of 37 serious adverse events (AEs), including 3 deaths, and 171 AEs were r …
In the simvastatin arm, participants entered a 1-month phase of simvastatin, 40 mg daily, followed by 23 months of simvasta
Treatment With Simvastatin and Rifaximin Restores the Plasma Metabolomic Profile in Patients With Decompensated Cirrhosis.
Pose E, Solà E, Lozano JJ, Juanola A, Sidorova J, Zaccherini G, de Wit K, Uschner F, Tonon M, Kazankov K, Jiménez C, Campion D, Napoleone L, Ma AT, Carol M, Morales-Ruiz M, Alessandria C, Beuers U, Caraceni P, Francoz C, Durand F, Mookerjee RP, Trebicka J, Vargas V, Piano S, Watson H, Abraldes JG, Kamath PS, Davis MM, Ginès P; investigators of the LIVERHOPE Consortium. Pose E, et al. Hepatol Commun. 2022 May;6(5):1100-1112. doi: 10.1002/hep4.1881. Epub 2021 Dec 28. Hepatol Commun. 2022. PMID: 34964311 Free PMC article. Clinical Trial.
An ACLF-specific signature was identified. Treatment with simvastatin and rifaximin was associated with changes in 161 of 985 metabolites in comparison to treatment with placebo. ...Notably, 18 of the 32 metabolites of the ACLF signature were affected by the treatment. Con …
An ACLF-specific signature was identified. Treatment with simvastatin and rifaximin was associated with changes in 161 of 985 metabol …
Can simvastatin reduce COPD exacerbations? A randomised double-blind controlled study.
Schenk P, Spiel AO, Hüttinger F, Gmeiner M, Fugger J, Pichler M, Pichler G, Schmeikal S, Janistyn W, Schügerl S, Sajdik C, Herkner H. Schenk P, et al. Eur Respir J. 2021 Jul 29;58(1):2001798. doi: 10.1183/13993003.01798-2020. Print 2021 Jul. Eur Respir J. 2021. PMID: 33574076 Free article. Clinical Trial.
Hazard ratio for risk of first exacerbation for the simvastatin group was 0.51 (95% CI 0.34-0.75; p=0.001). Rate of exacerbations was significantly lower with simvastatin: 103 (41%) versus 147 (59%) (p=0.003). ...We found no effect on quality of life, lung function, …
Hazard ratio for risk of first exacerbation for the simvastatin group was 0.51 (95% CI 0.34-0.75; p=0.001). Rate of exacerbations was …
Simvastatin modulates estrogen signaling in uterine leiomyoma via regulating receptor palmitoylation, trafficking and degradation.
Afrin S, El Sabeh M, Islam MS, Miyashita-Ishiwata M, Malik M, Catherino WH, Akimzhanov AM, Boehning D, Yang Q, Al-Hendy A, Segars JH, Borahay MA. Afrin S, et al. Pharmacol Res. 2021 Oct;172:105856. doi: 10.1016/j.phrs.2021.105856. Epub 2021 Aug 28. Pharmacol Res. 2021. PMID: 34461224 Free PMC article. Clinical Trial.
To explain simvastatin effects on ER-alpha level and trafficking, we examined its effects on ER-alpha post-translational processing. ...Thus, our data suggest that simvastatin modulates several E(2)/ER signaling targets with potential implications in leiomyoma thera …
To explain simvastatin effects on ER-alpha level and trafficking, we examined its effects on ER-alpha post-translational processing. …
Simvastatin Augmentation for Patients With Early-Phase Schizophrenia-Spectrum Disorders: A Double-Blind, Randomized Placebo-Controlled Trial.
Sommer IE, Gangadin SS, de Witte LD, Koops S, van Baal C, Bahn S, Drexhage H, van Haren NEM, Veling W, Bruggeman R, Martens P, Wiersma S, Veerman SRT, Grootens KP, van Beveren N, Kahn RS, Begemann MJH. Sommer IE, et al. Schizophr Bull. 2021 Jul 8;47(4):1108-1115. doi: 10.1093/schbul/sbab010. Schizophr Bull. 2021. PMID: 33608711 Free PMC article. Clinical Trial.
Augmentation with drugs that lower this pro-inflammatory status may improve clinical presentation. Simvastatin crosses the blood-brain barrier, has anti- inflammatory and neuroprotective effects and reduces metabolic syndrome. In this study, we investigated if 12 months of …
Augmentation with drugs that lower this pro-inflammatory status may improve clinical presentation. Simvastatin crosses the blood-brai …
Differential effects of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I are consistent across hypercholesterolemic patient subgroups.
Davidson MH, Ose L, Frohlich J, Scott RS, Dujovne CA, Escobar ID, Bertolami MC, Cihon F, Maccubbin DL, Mercuri M. Davidson MH, et al. Clin Cardiol. 2003 Nov;26(11):509-14. doi: 10.1002/clc.4960261106. Clin Cardiol. 2003. PMID: 14640465 Free PMC article. Review.
HYPOTHESIS: Recent studies have shown that treatment with simvastatin results in larger increases in HDL-C than those seen with atorvastatin. ...CONCLUSION: The data presented show that, across different hypercholesterolemic patient subgroups, simvastatin increases …
HYPOTHESIS: Recent studies have shown that treatment with simvastatin results in larger increases in HDL-C than those seen with atorv …
1,710 results